LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bellus Health (BLU) is a stock that can certainly grab the ...

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

(Reuters) -GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies. The move to replenish ...

Canadian biotech Bellus Health (NASDAQ:BLU) announced Wednesday Phase 1 data for its lead asset camlipixant (BLU-5937), highlighting results as a demonstration of its proof of concept as an ...

LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a promising chronic cough drug to its pipeline. The all-cash deal values Bellus, based in Laval, Canada, at $14.75 a ...

Bellus Health BLU and GSK plc GSK announced that the former got an offer to be acquired by the latter for $14.75 per share of common stock in cash, representing an approximate total equity value of $2 ...

GSK is set to acquire Bellus Health for $14.75 per share of common stock in cash representing an approximate total equity value of $2 billion. Bellus is a Canada-based, late-stage biopharmaceutical ...

An audio webcast from the H.C. Wainwright event may be accessed on the Events and Presentations page under the Investors & Media section of BELLUS Health’s website at www.bellushealth.com. Following ...